Bio-ethylene Production: from Reaction Kinetics to Plant Scale

Ethylene production from renewable bio-ethanol has been recently proposed as sustainable alternative to fossil sources. The possibility to exploit diluted bioethanol as less expensive feedstock was studied both experimentally, using different catalysts at lab-level, and through preliminary process design. In this work, a full-scale plant simulation is presented, built on a detailed reaction kinetics. Rate equations for the primary and side reactions are revised and implemented with a process simulation package, using a range of thermodynamic methods as best suited to the different process stages. The catalyst loading within the reactor can be effectively distributed according to the underlying kinetic, and the overall plant layout let foresee the best routes for the material recycles. The detailed reaction modeling and the choice of the thermodynamic models are essential to obtain reliable predictions. Setting a target yield of 105 t/year of polymer-grade ethylene, the reactive section must be fed with 76 t/h of diluted ethanol and operated at 400 \ub0C. 85% of the fed carbon mass is found as ethylene, 12% remains as ethanol and a 2% as longer olefins. Considering also the recycle of ethanol the carbon conversion and recovery increases to the value of 97.6%. The global ethylene recovery is 90.7%: most of the loss takes place in the last stage due to the non-condensable purification and to the adopted strategy of having low reflux ratio \u2013 and then a closed cryogenic balance \u2013 in the last purification column. Full heat integration of the process with upstream bioethanol production and purification sections allows process intensification and consistent energy savings. This newly designed process sets the sustainable ethylene production on a detailed and reassessed computational basis and has been assessed as for Capital and Operational Expenditures and Total Investment costs

Prévenir les troubles musculosquelettiques chez les soignants : connaître les expositions et étude des outils d’aide à la manutention

ObjectifsDans le cadre de la Caisse nationale de retaite des agents des collectivités locales (CNRACL), la démarche d’évaluation et de prévention des risques vise à conduire à une démarche spécifique au milieu hospitalier et à construire des outils d’évaluation des risques dans le réseau des CHU français. Les études menées sur la prévention des troubles musculosquelettiques (TMS) associent principalement les compétences en ergonomie, épidémiologie et médecine du travail des CHU d’Angers et de Grenoble. Méthode Une première étude épidémiologique a permis d’identifier les facteurs de risque de TMS et de lombalgie en milieu hospitalier ; une seconde s’est intéressée à l’évaluation des outils d’aide à la manutention des patients en milieu de soins sous un angle ergonomique. Résultats Les salariés du secteur santé sont en moyenne exposés à 2,4 facteurs de risque des 19 répertoriés (3,5 pour le reste du réseau) et ne souffrent pas plus de TMS des membres supérieurs que les autres salariés de la région des Pays-de-la-Loire. En revanche, les expositions aux manutentions manuelles de charges lourdes liées aux soins aux patients sont plus fréquentes. Les aides techniques pour la manutention étudiées ne répondent pas aux critères de dépendance du patient ou aux conditions organisationnelles du service. Du point de vue psychologique, le rapport du patient au matériel ainsi que l’usage du corps du soignant dans la relation aux soins doivent être pris en compte. Conclusion L’approche biomécanique a fait l’objet de cette première investigation. Il s’agit d’une démarche de prévention pluridisciplinaire intégrée dans la politique d’établissement

Effect of lifestyle factors on Staphylococcus aureus gut colonization in Swedish and Italian infants

n/

Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor

We demonstrated that γδ T cells of patients given HLA-haploidentical HSCT after removal of αβ+ T cells and CD19+ B cells are endowed with the capacity of killing leukemia cells after ex vivo treatment with zoledronic acid (ZOL). Thus, we tested the hypothesis that infusion of ZOL in patients receiving this type of graft may enhance γδ T-cell cytotoxic activity against leukemia cells. ZOL was infused every 28 d in 43 patients; most were treated at least twice. γδ T cells before and after ZOL treatments were studied in 33 of these 43 patients, till at least 7 mo after HSCT by high-resolution mass spectrometry, flow-cytometry, and degranulation assay. An induction of Vδ2-cell differentiation, paralleled by increased cytotoxicity of both Vδ1 and Vδ2 cells against primary leukemia blasts was associated with ZOL treatment. Cytotoxic activity was further increased in Vδ2 cells, but not in Vδ1 lymphocytes in those patients given more than one treatment. Proteomic analysis of γδ T cells purified from patients showed upregulation of proteins involved in activation processes and immune response, paralleled by downregulation of proteins involved in proliferation. Moreover, a proteomic signature was identified for each ZOL treatment. Patients given three or more ZOL infusions had a better probability of survival in comparison to those given one or two treatments (86% vs. 54%, respectively, p = 0.008). Our data indicate that ZOL infusion in pediatric recipients of αβ T- and B-cell-depleted HLA-haploidentical HSCT promotes γδ T-cell differentiation and cytotoxicity and may influence the outcome of patients

Acetonitrile from Bioethanol Ammoxidation : Process Design from the Grass-Roots and Life Cycle Analysis

The growing interest for new routes to obtain acetonitrile led to the development of catalysts active toward the ammoxidation of various substrates. Among these, a C2 molecule such as ethanol represents a good choice in terms of atom economy and, being renewable, sets the basis for a long-term sustainable process. This paper describes a fully integrated, newly designed process for the production of acetonitrile from bioethanol, currently not present in the literature. The target is the production and purification of 10 kg/h of acetonitrile, unit of production used for calculations, obtained from ethanol, ammonia, and air as raw materials. All the byproducts, mainly ammonium bicarbonate and sodium cyanide, are considered marketable chemicals and represent an added value, instead of a disposal issue. Their optimized recovery is included in this flowsheet as a basis for the future economic assessment of the system. The process consumes CO2 without its direct emission. In principle, all the carbon atoms and 90% of the nitrogen atoms are turned into reaction products, and the main loss is gaseous N2. The process design has been performed by means of the Aspen PLUS process simulator, on the basis of literature data and other experimental results. In addition, for an evaluation of the potential benefits of the innovative biobased route, a life cycle analysis was carried out including all the stages involved in the bioacetonitrile production (from raw materials extraction up to the gate plant). The results were then compared with those achieved for the traditional fossil route (SOHIO process), showing a sensible decrease of the environmental burdens in terms of nonrenewable resources and damage to ecosystems (e.g., toxicity, climate change, etc.). Finally, a simplified sensitivity analysis was carried out by substituting the starting raw material for the production of bioethanol (corn) with other materials conventionally used worldwide, such as sugar cane and wood. The latter option seems to make the system more competitive in terms of carbon neutrality, thanks to the usage of the residual lignocellulosic fraction available on the market

IgE antibody repertoire in nasal secretions of children and adults with seasonal allergic rhinitis: a molecular analysis

Background: There is growing interest both in testing IgE in nasal secretions (NS) and in molecular diagnosis of seasonal allergic rhinitis (SAR). Yet, the reliability of nasal IgE detection with the newest molecular assays has never been assessed in a large cohort of pollen allergic patients. Objective: To investigate with microarray technology and compare the repertoires of specific IgE (sIgE) antibodies in NS and sera of a large population of children and adults with SAR. Methods: Nasal secretions were collected with an absorbent device (Merocel 2000®, Medtronic) and a minimal dilution procedure from 90 children and 71 adults with SAR. Total IgE (tIgE) (ImmunoCAP, Thermo Fisher Scientific (TFS)) and sIgE antibodies against 112 allergen molecules (ISAC-112, TFS) were measured in NS and serum. Results: Nasal sIgE was detectable in 68.3% of the patients. The detected nasal sIgE antibodies recognized airborne (88%), vegetable (10%), and animal food or other (<1%) allergen molecules. The prevalence and average levels of sIgE in NS and serum were highly interrelated at population level. A positive nasal sIgE antibody to a given molecule predicted the detection of the same antibody in the patient's serum with a specificity of 99.7% and a sensitivity of 40%. Conclusions: The concentration of sIgE is much lower in nasal secretions than in the serum. sIgE assays with very high analytical sensitivity and sampling methods with minimal dilution will be therefore needed to validate nasal secretions as alternative to serum in testing the sIgE repertoire

Heterogeneous validity of daily data on symptoms of seasonal allergic rhinitis recorded by patients using the e-diary AllergyMonitor®

Background: Patient-generated symptom and medication scores are essential for diagnostic and therapeutic decisions in seasonal allergic rhinitis (SAR). Previous studies have shown solid consistencies between different scores at population level in real-life data and trials. For clinicians, the evaluation of individual data quality over time is essential to decide whether to rely on these data in clinical decision-making. Objective: To analyze the consistency of different symptom (SS) and symptom medication scores (SMSs) at individual level in two study cohorts with different characteristics and explore individual patient trajectories over time. Methods: Within the pilot phase of the @IT.2020 project on diagnostic synergy of mobile health and molecular IgE assessment in patients with SAR, we analyzed data of 101 children and 93 adults with SAR and instructed them to record their symptoms and medication intake daily via the mobile app AllergyMonitor®. We then assessed the correlation between different SMS and a visual analogue scale (VAS) on the impact of allergy symptoms on daily life at population and individual level. Results: At population level, the Rhinoconjunctivitis total symptom score (RTSS) correlated better with VAS than the combined symptom and medication score (CSMS). At individual level, consistency among RTSS and VAS was highly heterogeneous and unrelated to disease severity or adherence to recording. Similar heterogeneity was observed for CSMS and VAS. Conclusions: The correlation of clinical information provided by different disease severity scores based on data collected via electronic diaries (e-diaries), is sufficient at population level, but broadly heterogeneous for individual patients. Consistency of the recorded data must be examined for each patient before remotely collected information is used for clinical decision making